PMID- 36852518
OWN - NLM
STAT- MEDLINE
DCOM- 20230414
LR  - 20230502
IS  - 2324-9269 (Electronic)
IS  - 2324-9269 (Linking)
VI  - 11
IP  - 4
DP  - 2023 Apr
TI  - Haplotype-dependent HLA-DRB1-DQB1 susceptibility to occult HBV infection in Xi'an 
      Han population.
PG  - e2102
LID - 10.1002/mgg3.2102 [doi]
LID - e2102
AB  - BACKGROUND: Occult hepatitis B virus (HBV) infection (OBI) is primarily 
      characterized by the persistence of HBV-DNA in the liver tissues and/or in the 
      serum without detectable HBsAg. Human leukocyte antigen (HLA) polymorphisms have 
      been found to be strongly associated with HBV in different ethnic backgrounds. 
      The association of HLA-DRB1-DQB1 haplotypes with OBI has not been previously 
      reported in China. The aim of this study was to identify the potential 
      association of HLA-DRB1-DQB1 haplotypes that may be involved in OBI genetic 
      susceptibility. METHODS: A case-control study was conducted between 107 OBI 
      subjects and 280 healthy controls from the blood donors in the Shaanxi Province 
      Blood Center. The HLA-DRB1, DQB1 loci were genotyped using polymerase chain 
      reaction-sequence based typing (PCR-SBT). Based on the genotype data of the two 
      loci, haplotype estimation was performed. RESULTS: HLA-DRB1*07:01-DQB1*02:02 
      (pc = 0.344 x 10(-3) , OR = 3.489, 95%CI = 2.000-6.088) and 
      HLA-DRB1*09:01-DQB1*03:03 (pc = 0.02, OR = 2.370, 95%CI = 1.450-3.873) serve as 
      the possible risk and susceptibility haplotypes for OBI in Xi'an Han after 
      Bonferroni correction. CONCLUSIONS: This study demonstrated that HLA II 
      haplotypes were significantly associated with OBI in the Xi'an Han population. To 
      the best of our knowledge, this is the first study to associate HLA-DRB1-DQB1 
      haplotypes with OBI, which can provide valuable insights into the relationship 
      between the various genetic factors and immune responses in the Xi'an population. 
      The findings can also form the basis for future studies about the role of HLA in 
      OBI.
CI  - (c) 2022 The Authors. Molecular Genetics & Genomic Medicine published by Wiley 
      Periodicals LLC.
FAU - Wang, Tianju
AU  - Wang T
AUID- ORCID: 0000-0001-7900-4757
AD  - Shaanxi Province Blood Center, Xi'an, People's Republic of China.
FAU - Shen, Chunmei
AU  - Shen C
AD  - Shaanxi Province Blood Center, Xi'an, People's Republic of China.
FAU - Qi, Jun
AU  - Qi J
AUID- ORCID: 0000-0002-8795-3140
AD  - Shaanxi Province Blood Center, Xi'an, People's Republic of China.
FAU - Chen, Liping
AU  - Chen L
AD  - Shaanxi Province Blood Center, Xi'an, People's Republic of China.
FAU - Liu, Sheng
AU  - Liu S
AD  - Shaanxi Province Blood Center, Xi'an, People's Republic of China.
FAU - Li, Hengxin
AU  - Li H
AUID- ORCID: 0000-0002-5547-0080
AD  - Shaanxi Province Blood Center, Xi'an, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230227
PL  - United States
TA  - Mol Genet Genomic Med
JT  - Molecular genetics & genomic medicine
JID - 101603758
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DQ beta-Chains)
SB  - IM
MH  - Humans
MH  - Case-Control Studies
MH  - Gene Frequency
MH  - Haplotypes
MH  - *Hepatitis B/genetics
MH  - Hepatitis B virus
MH  - *Hepatitis B, Chronic
MH  - *HLA-DRB1 Chains/genetics
MH  - *HLA-DQ beta-Chains/genetics
PMC - PMC10094095
OTO - NOTNLM
OT  - Xi'an Han population
OT  - haplotype frequency
OT  - human leukocyte antigen
OT  - occult HBV infection
COIS- The authors declare that they have no conflict of interest.
EDAT- 2023/03/01 06:00
MHDA- 2023/04/14 06:42
PMCR- 2023/02/27
CRDT- 2023/02/28 03:15
PHST- 2022/07/04 00:00 [revised]
PHST- 2021/12/14 00:00 [received]
PHST- 2022/11/03 00:00 [accepted]
PHST- 2023/04/14 06:42 [medline]
PHST- 2023/03/01 06:00 [pubmed]
PHST- 2023/02/28 03:15 [entrez]
PHST- 2023/02/27 00:00 [pmc-release]
AID - MGG32102 [pii]
AID - 10.1002/mgg3.2102 [doi]
PST - ppublish
SO  - Mol Genet Genomic Med. 2023 Apr;11(4):e2102. doi: 10.1002/mgg3.2102. Epub 2023 
      Feb 27.